84 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
to kidney patients, a dedication that has driven our team to achieve this milestone. We believe this commitment uniquely positions the company to execute
8-K
EX-99.1
dzv iz2a6zv1u
26 Sep 23
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
4:47pm
8-K
EX-99.1
ln242qqba19 v1vo
7 Jun 23
Regulation FD Disclosure
7:31am
8-K
EX-99.1
llqznnl3dyb7w
8 May 23
Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
7:41am
8-K
EX-3.1
vl5prif97 dlvfz
28 Apr 23
Amendments to Articles of Incorporation or Bylaws
7:30am
DEFA14A
fknnl9 6fhk5ugi
21 Apr 23
Additional proxy soliciting materials
4:30pm